Format

Send to

Choose Destination
See comment in PubMed Commons below
J Transl Med. 2011 Nov 4;9:190. doi: 10.1186/1479-5876-9-190.

Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein.

Author information

1
Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy. antonia.radaelli@unimi.it.

Abstract

BACKGROUND:

Human papilloma virus (HPV)-16 is the most prevalent high-risk mucosal genotype. Virus-like-particle (VLP)-based immunogens developed recently have proven to be successful as prophylactic HPV vaccines, but are still too expensive for developing countries. Although vaccinia viruses expressing the HPV-16 L1 protein (HPV-L1) have been studied, fowlpox-based recombinants represent efficient and safer vectors for immunocompromised hosts due to their ability to elicit a complete immune response and their natural host-range restriction to avian species.

METHODS:

A new fowlpox virus recombinant encoding HPV-L1 (FPL1) was engineered and evaluated for the correct expression of HPV-L1 in vitro, using RT-PCR, immunoprecipitation, Western blotting, electron microscopy, immunofluorescence, and real-time PCR assays.

RESULTS:

The FPL1 recombinant correctly expresses HPV-L1 in mammalian cells, which are non-permissive for the replication of this vector.

CONCLUSION:

This FPL1 recombinant represents an appropriate immunogen for expression of HPV-L1 in human cells. The final aim is to develop a safe, immunogenic, and less expensive prophylactic vaccine against HPV.

PMID:
22053827
PMCID:
PMC3231814
DOI:
10.1186/1479-5876-9-190
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center